Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Study Design

Type
Clinical Trial
Population
612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery
Methods
evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells); patients took 1 stick/daily for 8 weeks
Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®, an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients undergoing digestivesurgery.

Research Insights

SupplementDoseHealth OutcomeEffect TypeEffect SizeSource
Lactobacillus plantarum LP01Improved Stool FormationBeneficial
Moderate
View source

and improved stool form

Lactobacillus plantarum LP01Reduced Gastrointestinal SymptomsBeneficial
Moderate
View source

Abincol® significantly diminished the presence and the severity of intestinal symptoms

Back to top